Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
Status:
Enrolling by invitation
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
UX023-CL203 is a Phase 2b, open-label, long-term extension study. The study will be
conducted in adults to assess the safety and pharmacodynamics of KRN23 administered via
subcutaneous injections monthly (every 4 weeks) for a total of 68 weeks. The study will
enroll approximately 25 adults with XLH who participated in Kyowa Hakko Kirin Pharma, Inc.'s
(KHK's) study KRN23-INT-001 or KRN23-INT-002. Subjects will need to discontinue oral
phosphate and vitamin D metabolite therapy prior to enrollment and throughout the duration
of the study.